Phase 2 Chronic Kidney Disease Trial, Recruiting NCT07194590 Sponsor: University of Colorado, Denver Condition: Chronic Kidney Disease
Back to Chronic Kidney Disease

Phase 2 Chronic Kidney Disease Trial, Recruiting

NCT07194590
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Women who have gone through menopause
  • People aged 50 years or older
  • People with moderate-to-severe chronic kidney disease (CKD stage 3 or 4), meaning kidney function is reduced but not at the point of needing dialysis, and kidney function has been stable for the past 3 months (confirm with trial site for specific kidney function measurements)
  • People who eat soy-based foods fewer than 2 times per week on average
  • People whose weight has not changed by more than 2 kg in the past 3 months, and who are willing to keep their weight stable for the length of the study
  • People who are able to give their own informed consent to participate

Who may not be able to join:

  • People with advanced kidney disease who are already on regular dialysis
  • People in the CKD group whose blood pressure is not well controlled (above 140/90 mmHg)
  • People currently using any form of hormone replacement therapy
  • People with an allergy or intolerance to soy or soy-based products
  • People with certain liver test results that are significantly above the normal range (confirm with trial site for specific values)
  • People with a history of breast cancer
  • People with serious health conditions where life expectancy is less than 1 year
  • People who currently smoke or use nicotine products, or who have done so in the past 12 months
  • People who have had a kidney transplant
  • People with a history of severe heart failure (specifically where the heart is pumping at less than 35% of its normal capacity)
  • People who have been hospitalised in the past month
  • People who have taken immunosuppressant medications (drugs that reduce the immune system's activity) in the past 12 months
  • People with a known cancer diagnosis

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 303-724-3765

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
19 February 2026
Est. completion
30 November 2030

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Brachial Artery Flow-Mediated Dilation (FMDBA)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov